Abstract
Results of 2 phase I studies of intravenous (iv) pelitrexol (AG2037), a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor, in patients (pts) with solid tumors
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have